Eledon Pharmaceuticals (ELDN) Income towards Parent Company (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Income towards Parent Company data on file, last reported at -$21.3 million in Q1 2026.

• Quarterly Income towards Parent Company fell 12.28% year-over-year to -$21.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.8 million (up 16.44% YoY) and the FY2025 annual result came in at -$45.6 million, down 26.07% from the prior year.
• Income towards Parent Company eased to -$21.3 million in Q1 2026, from -$19.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$9.2 million in Q2 2022 to a low of -$58.4 million in Q4 2022.
• A 5-year average of -$18.1 million and a median of -$13.4 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 563.0% — and 2023, when it surged 82.12%.
• Tracing ELDN's Income towards Parent Company over 5 years: stood at -$58.4 million in 2022, then surged by 82.12% to -$10.4 million in 2023, then tumbled by 137.64% to -$24.8 million in 2024, then climbed by 19.91% to -$19.9 million in 2025, then dropped by 7.13% to -$21.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$21.3 million (Q1 2026), -$19.9 million (Q3 2025), and -$25.6 million (Q2 2025), per Business Quant data.